Jacobs Levy Equity Management
AMRX icon

Jacobs Levy Equity Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-97,379
Closed -$810K – 933
2024
Q3 		$810K Sell
97,379
-189,881
-66% -$1.48M ﹤0.01% 765
2024
Q2 		$1.82M Sell
287,260
-57,988
-17% -$368K 0.01% 620
2024
Q1 		$2.09M Sell
345,248
-54,985
-14% -$310K 0.01% 591
2023
Q4 		$2.43M Buy
400,233
+300,832
+303% +$1.34M 0.01% 572
2023
Q3 		$419K Buy
99,401
+71,975
+262% +$268K ﹤0.01% 835
2023
Q2 		$85K Sell
27,426
-1,953,020
-99% -$4.16M ﹤0.01% 950
2023
Q1 		$2.75M Buy
1,980,446
+278,411
+16% +$554K 0.02% 519
2022
Q4 		$3.39M Buy
1,702,035
+259,725
+18% +$582K 0.02% 462
2022
Q3 		$2.91M Sell
1,442,310
-81,866
-5% -$229K 0.02% 486
2022
Q2 		$4.85M Sell
1,524,176
-63,780
-4% -$231K 0.04% 426
2022
Q1 		$6.62M Sell
1,587,956
-113,101
-7% -$501K 0.04% 369
2021
Q4 		$8.15M Sell
1,701,057
-181,129
-10% -$903K 0.05% 343
2021
Q3 		$10.1M Sell
1,882,186
-217,748
-10% -$1.1M 0.07% 296
2021
Q2 		$10.8M Buy
2,099,934
+436,882
+26% +$2.48M 0.07% 277
2021
Q1 		$11.2M Buy
1,663,052
+948,233
+133% +$5.26M 0.09% 270
2020
Q4 		$3.27M Buy
714,819
+414,546
+138% +$1.84M 0.03% 479
2020
Q3 		$1.17M Buy
300,273
+230,224
+329% +$985K 0.01% 628
2020
Q2 		$333K Sell
70,049
-177,725
-72% -$732K ﹤0.01% 867
2020
Q1 		$862K Buy
+247,774
New +$1.05M 0.01% 661
2019
Q4 		– Sell
-200,600
Closed -$582K – 993
2019
Q3 		$582K Buy
200,600
+165,800
+476% +$579K 0.01% 698
2019
Q2 		$250K Buy
+34,800
New +$356K ﹤0.01% 843

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jacobs Levy Equity Management's AMRX Position: Q4 2024 in Review

Jacobs Levy Equity Management sold out of Amneal Pharmaceuticals (AMRX) in Q4 2024, closing a stake of 97,379 shares — an estimated $810K sold.

Jacobs Levy Equity Management first reported a position in AMRX in Q2 2019 and held it in 21 quarters. The position peaked at $11.2M in Q1 2021. 199 funds tracked by Wall St. Rank hold AMRX as of Q4 2024.

  • Jacobs Levy Equity Management reported no remaining Amneal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 97,379 Amneal Pharmaceuticals shares in Q4 2024, an estimated $810K.
  • Jacobs Levy Equity Management first reported a position in Amneal Pharmaceuticals in Q2 2019 and held it in 21 quarters.
  • Jacobs Levy Equity Management's Amneal Pharmaceuticals position peaked at $11.2M in Q1 2021.
  • 199 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2024, filed 14 Feb 2025.